Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients

Palella F.J. Jr , Chmiel J.S. , Moorman A.C. , Holmberg S.D. Durability and predictors of success of highly active anti-retroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617–1626.

Gazzard B. , Bernard A.J. , Boffito M. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487–503.

Boffito M. , Acosta E. , Burger D. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther 2005; 10: 469–477.

Piliero P.J. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004; 37 (Suppl 1): S2–S12.

Kewn S. , Hoggard P.G. , Sales S.D. Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002; 46: 135–143.

Ziagen® [abacavir]. Summary of Product Characteristics. GlaxoSmithKline, Research Triangle Park, NC 27709, USA. October 2006.

Hawkins T. , Veikley W. , St Claire R.L. III , Guyer B. , Clark N. , Kearney B.P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39: 406–411.

Moyle G.J. , DeJesus E. , Cahn P. , Castillo Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38: 417–425.

McDowell J.A. , Chittick G.E. , Stevens C.P. , Edwards K.D. , Stein D.S. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44: 1686–1690.

Aptivus® [tipranavir]. Summary of Product Characteristics. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877, USA. June 2006.

Swainston Harrison T. , Scott L.J. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005; 65: 2309–2336.

Oldfield V. , Plosker G.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2006; 66: 1275–1299.

Yeh R.F. , Gaver V.E. , Patterson K.B. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52–60.

Agarwala S. , Eley T. , Villegas C. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy. 28–30 April 2005, Quebec City, Quebec, Canada. Abstract 16.

Kearney B.P. , Mathias A. , Mittan A. , Sayre J. , Ebrahimi R. , Cheng A.K. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278–283.

Verweij-van Wissen C.P. , Aarnoutse R.E. , Burger D.M. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816: 121–129.

Dickinson L. , Robinson L. , Tjia J. , Khoo S. , Back D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829: 82–90.

Smith C.M. , Faucette S.R. , Wang H. , LeCluyse E.L. Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J Biochem Mol Toxicol 2005; 19: 96–108.

Zhang D. , Chando T.J. , Everett D.W. , Patten C.J. , Dehal S.S. , Humphreys W.G. In vitro inhibition of UDP glucuronosyl-transferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33: 1729–1739.

Ouellet D. , Hsu A. , Qian J. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46: 111–116.

Fichtenbaum C.J. , Gerber J.G. , Rosenkranz S.L. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569–577.

Tseng A. , Fletcher D. Interaction between ritonavir and levothyroxine. AIDS 1998; 12: 2235–2236.

van der Lee M.J. , Dawood L. , ter Hofstede H.J. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006; 80: 159–168.

Eron J. , Yeni P. , Gathe J. The KLEAN study of fosam-prenaivr-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for the initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet 2006; 368: 476–482.

Hoggard P.G. , Back D.J. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr Opin Infect Dis 2002; 15: 3–8.

Jullien V. , Treluyer J.M. , Chappuy H. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br J Clin Pharmacol 2005; 59: 183–188.